top of page
Browse by category
Search
Structure Therapeutics selects oral small molecule amylin receptor agonist ACCG-2671 for obesity treatment
Structure Therapeutics has selected its lead oral small molecule amylin receptor agonist, ACCG-2671, which the company will develop for...
Reduced complication-related costs and enhanced patient recovery using the Ezisurg Endostapler
Bariatric and metabolic surgery (BMS) using the easyEndo™ Lite Endostapler (Ezisurg Medical) results in low rates of postoperative...
Fractyl unveils promising preclinical data demonstrating safety and feasibility of local delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy
Fractyl Health has presented new data from its preclinical Rejuva Smart GLP-1 pancreatic gene therapy program in a poster titled,...
Researchers to develop BIOSYNC wireless bioelectronic device to treat obesity and diabetes
A multidisciplinary team led by Ken Shepard, a pioneering researcher in bioelectronics at Columbia Engineering, has won an award of up to...
Serotonin plays key role in the development of post-bariatric hypoglycaemia
A study conducted at Harvard University has identified the central role of serotonin - a hormone involved in mood regulation - in the...
Decline in the number of patients seeking private BMS in the UK
There has been a marked decline in the number of patients seeking private bariatric and metabolic surgery (BMS) in the UK, from 5,900 in...
BioAge axes STRIDES trial evaluating azelaprag in combination with tirzepatide for the treatment of obesity
BioAge Labs is to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in...
Zealand Pharma enrols 1st patient in ZUPREME-1 trial of petrelintide
Zealand Pharma has enrolled the first participant has been enrolled in ZUPREME-1, a global Phase 2b trial in people with obesity or...
Introducing XNY Medical’s next-generation ENDO NOVA Powered Stapler
Bariatric News talked to Dr Jassim Fakhro, Senior Consultant in General, Metabolic, Bariatric and Robotic Surgery, Vice President of the...
SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...
Browse by tag
bottom of page